DXCOVER
LIVE

Serial Number

79299097

Owner

DXCOVER LIMITED

Attorney

Alex P. Garens

Filing Date

Sep 25, 2020

Add to watchlist:

No watchlists yet
View on USPTO

DXCOVER Trademark

Serial Number: 79299097 • Registration: 6481155

DXCOVER is a trademark filed by DXCOVER LIMITED on September 25, 2020. The trademark is classified under Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

DXCOVER LIMITED (4 trademarks)

Suite RC534, Royal College Building,

Entity Type: 99

Clinspec Diagnostics Limited

Suite RC534, Royal College Building,

Entity Type: 99

Trademark Details

Filing Date

September 25, 2020

Registration Date

September 14, 2021

Published for Opposition

June 1, 2021

Goods & Services

Scientific apparatus and instruments for analysing biofluids and detecting diseases; laboratory apparatus and instruments for microscopy; scientific apparatus, namely, spectrometers and parts and fittings therefor; spectroscopes; scientific apparatus, namely, spectrophotometers for measuring the infrared spectrum of biofluids for the purpose of detecting diseases; spectrometry apparatus; spectrograph apparatus; data processing equipment, namely, couplers; downloadable computer software for use in medical and clinical analysis and disease diagnostics for analyzing medical data to assist in providing clinical interpretations; computer hardware; downloadable electronic publications in the nature of newsletters, reports and brochures in the field of science and medicine; data processing apparatus with artificial intelligence; downloadable artificial intelligence and machine learning software for analyzing medical data to assist in providing clinical interpretations in the field of medical and clinical analysis and disease diagnostics; research laboratory analysers for measuring, testing and analysing blood and other bodily fluids; parts and fittings for all the aforesaid goods; all of the aforesaid goods relating to spectroscopic analysis

Medical services; medical care services; health clinic services; healthcare services, namely, medical analysis services for diagnostic and treatment purposes; medical diagnostic testing, monitoring, and reporting services; providing cancer screening services; preparation of medical reports relating to health care matters in the field of biofluid analysis and the detection of diseases for medical professionals and patients; medical testing for diagnostic or treatment purposes; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis services for the diagnosis of cancer; medical testing of blood; medical testing in the nature of liquid biopsy testing for medical purposes; advice, information and consultancy services for all of the aforesaid services; all of the aforesaid services relating to spectroscopic analysis

Medical apparatus and instruments for analysing biofluids and detecting diseases; diagnostic apparatus for medical purposes, namely, analysing biofluids and detecting diseases; medical apparatus for the treatment of cancer; blood testing apparatus; medical diagnostics instruments and apparatus for the analysis of bodily fluids; medical apparatus, instruments and devices for liquid biopsy analysis; parts and fittings for all the aforesaid goods; all of the aforesaid goods relating to spectroscopic analysis

Scientific and technological services, namely, research, design, analysis and testing in the field of medical and clinical analysis and disease diagnostics; industrial analysis and research services in the field of medical and clinical analysis and disease diagnostics; design and development of computer hardware and software; design and development of computer software for use with medical technology; engineering services and design services for scientific equipment and apparatus for microscopy, spectroscopy and scientific imaging; medical research services; clinical research in the field of biofluid analysis and disease detection; medical laboratory services; computer programming in the medical field; design and development of medical technology; design and development of medical diagnostic apparatus; blood analysis services; scientific research for medical purposes in the area of cancerous diseases; research in the field of artificial intelligence; providing on-line non-downloadable software using artificial intelligence for analyzing medical data to assist in providing clinical interpretations in the field of medical and clinical analysis and disease diagnostics; software as a service (SaaS) services featuring software using artificial intelligence for analyzing medical data to assist in providing clinical interpretations in the field of medical and clinical analysis and disease diagnostics; software as a service (SaaS) services featuring software for analyzing medical data to assist in providing clinical interpretations in the field of medical and clinical analysis and disease diagnostics; analysis and evaluation of technical data, namely, scientific and medical data for analyzing medical data to assist in providing clinical interpretations in the field of medical and clinical analysis and disease diagnostics; technical support services, namely, computerised analysis of technical data; scientific and technological services, namely, overseeing, monitoring and managing scientific and medical experiments and tests in the field of medical and clinical analysis and disease diagnostics; scientific and technological services, namely, overseeing, monitoring and managing the analysis and evaluation of scientific and medical data in the field of medical and clinical analysis and disease diagnostics; design of scientific experiments; provision of scientific reports relating to scientific research in the field of medical and clinical analysis and disease diagnostics; advice, information and consultancy services for all of the aforesaid services; all of the aforesaid services relating to spectroscopic analysis

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 21, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 1, 2022 FICS
FINAL DISPOSITION PROCESSED
Mar 1, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 14, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Sep 14, 2021 R.PR
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Aug 11, 2021 ETOP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 2, 2021 ADCH
EXTENSION OF TIME TO OPPOSE RECEIVED
Jul 1, 2021 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 1, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jun 1, 2021 PUBO
CHANGE OF NAME/ADDRESS REC'D FROM IB
May 15, 2021 ADCH
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 12, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 26, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 26, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 26, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 26, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 26, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 24, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 23, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 23, 2021 TROA
REFUSAL PROCESSED BY IB
Mar 22, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 4, 2021 RFCS
REFUSAL PROCESSED BY MPU
Mar 4, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 22, 2021 RFCR
NON-FINAL ACTION WRITTEN
Feb 21, 2021 CNRT
ASSIGNED TO EXAMINER
Feb 17, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 8, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 4, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 3, 2020 REPR